AzaSite Plus: SPA received

InSite received an SPA from FDA for the planned Phase III DOUBle trial to evaluate AzaSite Plus and DexaSite in 900 patients. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite veh...